Puhua Heshun is a leading medical device company focusing on the high-growth and high-profit segment of the Chinese medical device industry. The Group's current business divisions are infusion devices, blood purification products, and regenerative medical biomaterials, and it has a stable leading position in the market with strong R&D capabilities and a perfect distribution network. The Company's shares have been successfully listed on the main board of the Stock Exchange since November 8, 2013, thus enabling Pratt & Wah Heshun to enter the international capital market and establish a platform for the rapid development of its business. — The Group is a leading company in the infusion set business in China. The Group's products include non-PVC infusion sets, precision filter infusion devices, light-proof infusion devices, intravenous needle products, insulin needles, and insulin pens. The Group was one of the first manufacturers to obtain approval from the FDA to produce precision filtration infusion devices, and is one of the first three manufacturers approved by the FDA to manufacture non-PVC infusion devices. The Group also has an exclusive patented non-PVC double layer tube infusion device design. — The Group is a leading company in the field of blood purification business in China. The Group's products include high-throughput hemodialyzers, low-throughput hemodialysis devices, hemodialysis filters, hemoperfusion devices and dialysis machines. The Group is the first manufacturer in China to obtain a high-throughput hemodialyzer registration certificate. — The Group has strong R&D capabilities in the regenerative medical biomaterials sector. It uses leading, next-generation tissue regeneration material technology, a complete product pipeline, and a wide range of application scenarios, including hernia repair, burns, oral repair, breast repair, and cosmetic injections.